- Home
- HALO
as 11-26-2025 3:38pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.6B | IPO Year: | N/A |
| Target Price: | $73.33 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.74 | EPS Growth: | 56.68 |
| 52 Week Low/High: | $46.26 - $79.50 | Next Earning Date: | 11-03-2025 |
| Revenue: | $1,242,852,000 | Revenue Growth: | 31.19% |
| Revenue Growth (this year): | 32.47% | Revenue Growth (next year): | 24.31% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Torley Helen | HALO | PRESIDENT AND CEO | Nov 12 '25 | Sell | $70.99 | 20,000 | $1,410,990.47 | 741,001 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Nov 11 '25 | Sell | $68.81 | 20,000 | $1,382,600.50 | 741,001 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Nov 10 '25 | Sell | $69.01 | 20,000 | $1,374,338.60 | 741,001 | |
| Connaughton Bernadette | HALO | Director | Nov 10 '25 | Sell | $68.48 | 2,000 | $136,960.00 | 42,952 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 3 '25 | Sell | $70.14 | 20,000 | $1,380,638.14 | 741,001 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 2 '25 | Sell | $72.35 | 20,000 | $1,424,082.70 | 741,001 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 1 '25 | Sell | $75.40 | 20,000 | $1,507,024.28 | 741,001 | |
| Connaughton Bernadette | HALO | Director | Oct 1 '25 | Sell | $75.40 | 2,000 | $150,481.00 | 42,952 | |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Sep 22 '25 | Sell | $78.25 | 2,227 | $173,584.49 | 22,079 | |
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Sep 10 '25 | Sell | $75.61 | 20,000 | $1,514,267.12 | 22,079 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
Investor's Business Daily
6 days ago
This Medical Technology Leader Sees Profit Growth Topping 44%
GuruFocus.com
24 days ago
Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Highlights: Record Royalty Revenue and ...
Zacks
24 days ago
Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks
24 days ago
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
Associated Press Finance
24 days ago
Halozyme Therapeutics: Q3 Earnings Snapshot
MT Newswires
24 days ago
Halozyme Therapeutics Q3 Adjusted Earnings, Revenue Rise; 2025 Guidance Revised
PR Newswire
24 days ago
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.